In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Tenaya Therapeutics, with a price target of $5.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors including the positive safety reviews from independent Data Safety and Monitoring Boards (DSMB) for Tenaya Therapeutics’ ongoing clinical trials. The DSMBs have endorsed the continuation and dose escalation of the Phase 1b/2 MyPEAK-1 trial for TN-201 and the Phase 1b RIDGE-1 trial for TN-401, indicating a favorable safety profile. This progression supports the potential efficacy of Tenaya’s gene therapy programs in addressing MYBPC3-associated HCM and PKP2-associated ARVC.
Additionally, the interim data from the RIDGE natural history study highlights the potential of TN-401 in treating ARVC, providing further confidence in the company’s clinical development strategy. The study’s findings, which include insights into clinical characteristics and pre-existing antibodies, are expected to complement the ongoing development of TN-401. These advancements, coupled with the anticipated data updates, underpin Pantginis’s optimistic outlook on Tenaya Therapeutics’ stock.
According to TipRanks, Pantginis is an analyst with an average return of -15.4% and a 33.00% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Krystal Biotech, Cytokinetics, and Capricor Therapeutics.